Navigation Links
BioTrends Announces the Continuation of a Syndicated Report Series: TreatmentTrends: CKD Stages 1-5ND
Date:3/13/2013

EXTON, Pa., March 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, announces the continuation of the report series entitled TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis. BioTrends plans to field the third wave of this research similarly to the two waves conducted in 2012, with each wave consisting of findings from a quantitative survey with 250 physicians (100 nephrologists, 100 primary care physicians, and 50 endocrinologists). Below are some key findings from the second wave of this report series; these items and others will be tracked in the third wave of research to observe changes over time:

  • The majority of physicians feel that patients are referred to nephrologists too late, nephrologists are significantly more likely than PCPs to feel this way
  • According to nephrologists, the primary reason that PCPs refer CKD patients to nephrologists is based on a high creatinine level or rising creatinine levels
  • For many medication classes, treatment tends to increase as CKD worsens - by Stage 5ND, approximately forty percent of patients are on phosphate binders, approximately forty percent are on oral active Vitamin D, and just over twenty percent are on erythropoiesis-stimulating agents
  • Similar to the first wave of research, physicians tend to report moderate to high interest in Concert Pharmaceutical's CTP-499 and Mitsubishi Tanabe's AST-120
  • (Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

    TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis is a report series designed to track physician perception of the CKD-ND patient population, including referral patterns, patient load, current treatments, screening protocols, diagnosis patterns, frequency of comorbidities, unmet needs, and reaction to new products in development. TreatmentTrends: Chronic Kidney Disease Stages 1-5 Non-Dialysis, which is written by BioTrends Research Group nephrology experts, uses feedback provided directly from biotechnology and pharmaceutical organizations as well as nephrology thought leaders. Proprietary questions are solicited from key contacts at appropriate organizations. The third wave of this report will publish by July 3, 2013 with comments and proprietary questions for this wave due on March 22, 2013.

    About BioTrends Research Group
    BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit us at www.bio-trends.com. BioTrends is a Decision Resources Group company.

    About Decision Resources Group
    Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

    All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, LLCDecision Resources GroupRob Dubman

    Christopher Comfort781-993-2592

    781-993-2597rdubman@bio-trends.comccomfort@dresources.com 


    '/>"/>
    SOURCE BioTrends Research Group
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
    2. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
    3. PDI, Inc. Announces $17 Million Multi-Year Sales Contract
    4. BD Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development
    5. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
    6. HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
    7. Johnson & Johnson Announces Opening of London Innovation Centre
    8. GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2012
    9. Jensen Dental Announces Launch of the Preciso Digital Dentistry Solution; Includes New CAD/CAM Software and Website
    10. MedShape, Inc. Announces New 10mm DynaNail
    11. I-Flow Announces Bus Tour to Educate Care Providers on Acute Surgical Pain Management
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
    (Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
    (Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
    Breaking Medicine Technology:
    (Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
    (Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
    Breaking Medicine News(10 mins):